Select Language
CD45
CD45 Overview
| English Name | Leukocyte common antigen | Approved Drugs | 0 |
| Drugs in Clinical Trials | 7 | Target Synonym | PTPRC，T200，CD45，Protein Tyrosine Phosphatase， Receptor Type C，CD45 Antigen，L-CA，Protein Tyrosine Phosphatase， Receptor Type， C Polypeptide，Receptor-Type Tyrosine-Protein Phosphatase C，T200 Leukocyte Common Antigen，Leukocyte Common Antigen，T200 Glycoprotein，EC 3.1.3.48，CD45R，GP180，B220，LCA，LY5，Leukocyte Common Antigens，Protein Tyrosine Phosphatase Receptor Type C，EC:3.1.3.48 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Leukocyte common antigen |
| Target Synonym | PTPRC，T200，CD45，Protein Tyrosine Phosphatase， Receptor Type C，CD45 Antigen，L-CA，Protein Tyrosine Phosphatase， Receptor Type， C Polypeptide，Receptor-Type Tyrosine-Protein Phosphatase C，T200 Leukocyte Common Antigen，Leukocyte Common Antigen，T200 Glycoprotein，EC 3.1.3.48，CD45R，GP180，B220，LCA，LY5，Leukocyte Common Antigens，Protein Tyrosine Phosphatase Receptor Type C，EC:3.1.3.48 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 7 |
| Highest Development Stage | Phase 3 Clinical |
CD45 Product List
- Product Category
Protein (5)Antibody (3)
- Product Status
Launched (8)
- Species
Human (4)Mouse (4)
- Tag
His Tag & Avi Tag (2)His Tag (2)Llama IgG Fc Tag (1)- (3)
- Conjugate
Biotin-labeled (2)Unconjugated (3)PerCP-Cy5.5 Labeled (2)PE Labeled (1)
Total: 8
- 1
CD45 Background
CD45 is a receptor protein tyrosine phosphatase, also known as Ly-5 or leukocyte common antigen. CD45 mainly involves in the initiation of T cell receptor signaling by controlling the activation of the Src family protein-tyrosine kinases Lck and Fyn. CD45 deficiency causes in T- and B-lymphocyte dysfunction in the form of severe combined immune deficiency. It also takes a significant role in autoimmune diseases and cancer as well as in infectious diseases including fungal infections.
CD45 Synonyms
CD45,PTPRC,L-CA,T200
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Cardiomyopathies; Endomyocardial Fibrosis | Details | |
| I-131-Apamistamab | BC8-I-131; BC-8; 131IBC8; I-131 BC-8 | Phase 3 Clinical | Fred Hutchinson Cancer Research Center | Anemia, Refractory, with Excess of Blasts; Anemia, Sickle Cell; Anemia, Sideroblastic; Angioimmunoblastic T-cell Lymphoma; Burkitt Lymphoma; Graft vs Host Disease; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Intraocular Lymphoma; Leukemia; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Gonadal Tissue; Neoplastic Cells, Circulating; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndro | Details |
| At 211 MAb BC8-B10 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Neoplasms | Details | |
| 211At-BC8-B10 | 211At-BC8-B10 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Hematologic Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD45BE-HSPC cells therapy (Kite Pharma) | Phase 1 Clinical | Kite Pharma | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, T-Cell; Richter's Syndrome | Details | |
| CART-45 cells therapy (Kite Pharma) | Phase 1 Clinical | Kite Pharma | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, T-Cell; Richter's Syndrome | Details | |
| TSC-102 | TSC-102-A03; TSC-102-A0301; TSC-102; TSC-102-A01 | Phase 1 Clinical | TScan Therapeutics Inc | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Product Reviews
n***l2025-10-31
0People LikeThe technical team was quick to respond to my question regarding my experimental plan to use the biotinylated CD45 PTPRC protein. The biotinylated protein was immobilized on the SA biosensor of Octet BLI R8 to measure the binding affinity of anti-human CD45RA antibody. The assay worked on the first try!- N***o2023-05-13 0People LikeWe were very satisfied with the whole process of purchasing and utilizing the product as we had no issues with shipping time or product packaging. We used the protein to assist in the development of LFAs detecting for CD45 on cells. Pairs of anti-CD45 antibodies were first tested using the protein to help us determine which pair of antibodies produced the best results. These tests allowed us to move forward with designing full LFAs.
- L***h2021-12-13 1People LikeDear Sir or Madam, I had an overall good service from Acro Biosystems. Shipment was fast and product quality was good. Got the protocol for QC after asking the customer service. Protocol for QC was easy to understand and repeat. Easy way to download the Certificate of Analysis via the printed QR code on product vials. Customer service answered very fast and was very friendly. QC of biotinylated human CD45 protein vs. Human Galectin-1 protein (GA1-H4113) was fine. Biotinylated human CD45 protein worked fine and could be loaded on Streptavidin biosensors (Octet system).
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main